Page last updated: 2024-11-13

[1-(cyclohexylmethyl)-3-piperidinyl]-(3,4-dimethoxyphenyl)methanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

**[1-(Cyclohexylmethyl)-3-piperidinyl]-(3,4-dimethoxyphenyl)methanone** is a chemical compound that is a synthetic analog of the naturally occurring alkaloid, **piperine**, the active component of black pepper.

**Structure and Properties:**

* It consists of a piperidine ring substituted at position 3 with a cyclohexylmethyl group and a phenyl group attached to the nitrogen atom.
* The phenyl group is further substituted with two methoxy groups at positions 3 and 4.
* This compound is a solid at room temperature.

**Research Importance:**

[1-(Cyclohexylmethyl)-3-piperidinyl]-(3,4-dimethoxyphenyl)methanone has been investigated for its potential therapeutic applications in several areas:

**1. Analgesic and Anti-inflammatory Activity:**
* Studies have shown that this compound possesses analgesic and anti-inflammatory properties, comparable to or even exceeding those of piperine.
* Its mechanism of action is thought to involve the inhibition of prostaglandin synthesis and the modulation of various inflammatory pathways.

**2. Anti-cancer Activity:**
* Research suggests that this compound may exhibit anti-cancer activity against various cancer cell lines.
* It has shown promise in inhibiting cancer cell proliferation and inducing apoptosis (programmed cell death).

**3. Antioxidant Activity:**
* The compound has demonstrated antioxidant activity, protecting cells from damage caused by free radicals.

**4. Neuroprotective Activity:**
* Studies have indicated potential neuroprotective effects of this compound.
* It has been shown to protect neurons from damage induced by oxidative stress and neurotoxins.

**5. Pharmacokinetic Properties:**
* The compound has been found to have favorable pharmacokinetic properties, such as good oral bioavailability and reasonable half-life, making it a potential candidate for drug development.

**Conclusion:**

[1-(Cyclohexylmethyl)-3-piperidinyl]-(3,4-dimethoxyphenyl)methanone is a promising compound with potential therapeutic applications in various fields. Its analgesic, anti-inflammatory, anti-cancer, antioxidant, and neuroprotective activities warrant further investigation and preclinical development. However, more research is needed to fully understand its safety and efficacy before it can be used clinically.

Cross-References

ID SourceID
PubMed CID44629413
CHEMBL ID1794268
CHEBI ID91664

Synonyms (7)

Synonym
BRD-A37656721-001-01-9
smr001596526
MLS002725684
CHEMBL1794268
CHEBI:91664
Q27163487
[1-(cyclohexylmethyl)-3-piperidinyl]-(3,4-dimethoxyphenyl)methanone
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency30.86780.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency19.95260.00527.809829.0929AID588855
VprHuman immunodeficiency virus 1Potency39.81071.584919.626463.0957AID651644
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID631975Cytotoxicity against mouse NIH/3T3 cells2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of small-molecule inhibitors of Trypansoma cruzi replication.
AID631974Antitrypanosomal activity against trypomastigote form of Trypanosoma cruzi Tulahuen expressing beta-galactosidase infected in mouse NIH/3T3 cells assessed as inhibition of parasite replication after 4 days by betagalactosidase-based luminescence assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of small-molecule inhibitors of Trypansoma cruzi replication.
AID631978Solubility of compound in phosphate buffered saline buffer2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of small-molecule inhibitors of Trypansoma cruzi replication.
AID631977Selectivity ratio of IC50 for mouse NIH/3T3 cells to IC50 for trypomastigote form of Trypanosoma cruzi Tulahuen2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Identification of small-molecule inhibitors of Trypansoma cruzi replication.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]